Compare TG Therapeutics Inc (TGTX) vs YPF Sociedad Anonima American Depositary Shares (YPF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs YPF Sociedad Anonima American Depositary Shares — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while YPF Sociedad Anonima American Depositary Shares trades at $50.04 (market cap $19.56B). The key difference: YPF Sociedad Anonima American Depositary Shares is far larger — about 2.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, YPF Sociedad Anonima American Depositary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and YPF Sociedad Anonima American Depositary Shares for 1 Days on average.
| TGTX | YPF | |
|---|---|---|
Market Cap | $8.16B | $19.56B |
Volume | 1,735,121 | 1,179,532 |
Sector | Health | Energy |
52-Week High | $59.06 | $57.61 |
52-Week Low | $26.94 | $24.71 |
Typical Hold Time | 16 Days | 1 Days |
Enterprise Value | $8.37B | $27.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About YPF Sociedad Anonima American Depositary Shares
YPF is an integrated energy company in Argentina. Its operations span oil and gas exploration and production, transportation, refining, and the marketing of petroleum products.
Read more on YPF →
